反応式
CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2.FC(F)(F)c1ccnc(Cl)c1>CC(C)(C)[O-].Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2c1cc(C(F)(F)F)ccn1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 105 °C
実験手順
A 2.0-5.0 mL microwave vial was charged with (1S,4S)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (200 mg, 1.01 mmol), rac-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (62.8 mg, 0.10 mmol), Sodium tert-butoxide (116 mg, 1.21 mmol), 2-Chloro-4-(trifluoromethyl)pyridine (0.156 mL, 1.21 mmol) and a mixture of toluene (2.5 mL) and DMF (.5 mL). The reaction mixture was degassed for 10 minutes with nitrogen, and then Tris(dibenzylideneacetone)dipalladium(0) (46.2 mg, 0.05 mmol) was added. The reaction mixture was stirred at 105°C in an oil bath 12h. The solution was diluted with EtOAc and washed with saturated NaHCO3 solution, brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude material was loaded on a 24g silica gel column and purified on a Teledyne Isco instrument, eluting with 10% to 40% ethyl acetate in heptane to provide (1S,4S)-tert-butyl 5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (254 mg, 73.3 %) as a solid. 1H NMR (400MHz ,CHLOROFORM-d) d 8.26 (d, J = 5.5 Hz, 1 H), 6.75 (d, J = 5.1 Hz, 1 H), 6.48 (s, 1 H), 4.99 - 4.83 (m, 1 H), 4.76 - 4.52 (m, 1 H), 3.56 (t, J = 8.4 Hz, 1 H), 3.49 - 3.32 (m, 3 H), 2.04 - 1.91 (m, 2 H), 1.45 (d, J = 18.0 Hz, 9 H); MS m/z 344.2 [M+H]+ (ESI).
出典と根拠
- ORDレコード
- ord-1d6228eeae6e455c9c2acbb4c4aa8214
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…